Myriad Genetics | MYGN - Ebit


Myriad Genetics reported $-3M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Agilent USD 399M 46M Mar/2026
Becton, Dickinson and Co. USD 627M 36M Mar/2026
Bio-Rad Laboratories USD 941.3M 1.36B Dec/2025
Bruker USD 10.2M 66.1M Mar/2026
Danaher USD 1.34B 158M Mar/2026
Illumina USD 239M 17M Mar/2026
J&J USD 6.62B 1.51B Mar/2026
Mettler Toledo International USD 233.93M 118M Mar/2026
Myriad Genetics USD -3M 20.3M Dec/2025
OraSure Technologies USD -13.59M 2.13M Dec/2025
Pacific Biosciences Of California USD -53.19M 35.08M Dec/2025
Quest Diagnostics USD 399M 13M Mar/2026
Quidel USD -27.4M 9.9M Mar/2026
Repligen USD 19.98M 13K Mar/2026
Revvity USD 82.77M 63.06M Mar/2026
Standard Biotools USD -21.92M 10.97M Dec/2025
Thermo Fisher Scientific USD 1.91B 389M Mar/2026
Veracyte USD 19.08M 5.55M Mar/2026
Waters USD 148M 122.52M Mar/2026